Results 91 to 100 of about 138,640 (301)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Increased mortality in hematological malignancy patients with acute respiratory failure from undetermined etiology : a Groupe de Recherche en Réanimation Respiratoire en Onco-Hématologique (Grrr-OH) study [PDF]

, 2016
Background: Acute respiratory failure (ARF) is the most frequent complication in patients with hematological malignancies and is associated with high morbidity and mortality.
Azoulay, Elie, Benoit, Dominique, Bruneel, Fabrice, Contejean, Adrien, Darmon, Michael, Hamidfar, Rebecca, Jourdain, Mercé, Kouatchet, Achille, Lemiale, Virginie, Mayaux, Julien, Meert, Anne-Pascale, Mokart, Djamel, Nyunga, Martine, Perez, Pierre, Pène, Frédéric, Rabbat, Antoine, Renault, Anne, Resche-Rigon, Matthieu, Schlemmer, Benoît, Vincent, François   +19 more
core   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. [PDF]

, 2017
The effect of prior malignancy on the risk of developing, and prognosis of, acute lymphoblastic leukemia (ALL) is unknown. This observational study utilized the California Cancer Registry to estimate the risk of developing ALL after a prior malignancy ...
Brunson, A, Jonas, BA, Keegan, THM, Paulus, JK, Rosenberg, AS, Tuscano, J, Wun, T   +6 more
core   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

A retrospective study on beta-blocker use and outcomes in hematopoietic stem cell transplant patients [PDF]

PeerJ
Recent studies have linked beta-blocker (BB) use in critical care settings with improved survival outcomes, potentially due to beta-adrenergic receptor (β-AR) blockade and associated anti-inflammatory effects.
Matthew A. Bergens, John T. Bokman, Ernaya J. Johnson, Matthew L. Braun, Yan Li, Amy T. Bush, Lauren Hill, Jolien Van Opstal, Alessandro Racioppi, Rebecca Fan, Sejal Kaushik, Edwin Alyea, Nelson Chao, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Richard Lopez, Sendhilnathan Ramalingam, Keith Sullivan, Paul Wischmeyer, Anthony D. Sung   +20 more
doaj   +2 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results [PDF]

, 2016
Aim: To report long term oncologic outcomes after adjuvant radiotherapy (RT) for stage I seminoma. Method: We reviewed the complete data set for all patients treated at our institute between 1988 and 2005 for stage I seminoma with adjuvant RT after ...
De Felice, Francesca, Gravina, Giovanni Luca, Marampon, Francesco, Musio, Daniela, Tombolini, Vincenzo   +4 more
core   +2 more sources